AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20105410 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician advice intervention
Number of subjects: 996
Study 20105410 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 996
Study 17651376 — intervention group
Group type: EXPERIMENTAL
Intervention: PHA-stimulated CBMC
Number of subjects: 98
Study 17651376 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-lactoglobulin-stimulated CBMC
Number of subjects: 98
Study 17651376 — intervention group
Group type: COMPARATOR
Intervention: Maternal probiotic supplementation
Number of subjects: 98
Study 15918929 — intervention group
Group type: EXPERIMENTAL
Intervention: Total alcohol consumption
Number of subjects: 2691
Study 15918929 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine consumption
Number of subjects: 2691
Study 15918929 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirits consumption
Number of subjects: 2691
Study 15918929 — intervention group
Group type: COMPARATOR
Intervention: Beer consumption
Number of subjects: 2691
Study 14569762 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing
Number of subjects: 102
Study 14569762 — intervention group
Group type: COMPARATOR
Intervention: Unreamed nailing
Number of subjects: 102
Study 9645907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular hemostasis device (VasoSeal)
Number of subjects: 0
Study 9645907 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 0
Study 8160607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with chest pain present at onset (n = 3000)
Number of subjects: 3337
Study 8160607 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis without chest pain present at onset (n = 337)
Number of subjects: 3337
Study 3371394 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol (CR), 200 mg/day
Number of subjects: 115
Study 3371394 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 100 mg twice daily
Number of subjects: 115
Study 3371394 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol (CR), 100 mg/day
Number of subjects: 115
Study 3371394 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 50 mg twice daily
Number of subjects: 115
Study 30477869 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum Acupuncture Group 1 (VA1, 3 times weekly for 4 weeks)
Number of subjects: 30
Study 30477869 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum Acupuncture Group 2 (VA2, twice weekly for 4 weeks)
Number of subjects: 30
Study 30477869 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture Group (SA, twice weekly for 4 weeks)
Number of subjects: 30
Study 26384960 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional rearing
Number of subjects: 69
Study 26384960 — intervention group
Group type: COMPARATOR
Intervention: Foster care (as part of the Bucharest Early Intervention Project)
Number of subjects: 69
Study 24135427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol, 2 mg/kg/day
Number of subjects: 45
Study 24135427 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical propranolol 1% ointment twice daily
Number of subjects: 45
Study 24135427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional propranolol, 1 mg in 1 ml injection once weekly
Number of subjects: 45
Study 24135427 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 20737274 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 53
Study 20737274 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 53
Study 19699864 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine stent-based percutaneous coronary intervention (PCI)
Number of subjects: 2201
Study 19699864 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2201
Study 16551713 — intervention group
Group type: COMPARATOR
Intervention: Physically active, normal weight women (energy expenditure >=1000 kcal/week; BMI 18.5-24.9)
Number of subjects: 27158
Study 16551713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive, normal weight women
Number of subjects: 27158
Study 16551713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active, overweight women
Number of subjects: 27158
Study 16551713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive, overweight women
Number of subjects: 27158
Study 16551713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active, obese women
Number of subjects: 27158
Study 16551713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive, obese women
Number of subjects: 27158
Study 16551713 — intervention group
Group type: COMPARATOR
Intervention: Physically active, normal weight women
Number of subjects: 27158
Study 15194376 — intervention group
Group type: EXPERIMENTAL
Intervention: D+/R- group
Number of subjects: 297
Study 15194376 — intervention group
Group type: EXPERIMENTAL
Intervention: D-/R- group
Number of subjects: 297
Study 15194376 — intervention group
Group type: COMPARATOR
Intervention: D+/R+, D-/R+, D-/R- groups collectively
Number of subjects: 297
Study 11518628 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate medium dosage (200 mg daily)
Number of subjects: 20
Study 11518628 — intervention group
Group type: COMPARATOR
Intervention: Topiramate low dosage (100 mg daily)
Number of subjects: 20
Study 9424901 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti H. pylori therapy
Number of subjects: 0
Study 7950197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong‐Mai oral liquid (Traditional Chinese Medicine)
Number of subjects: 65
Study 7950197 — intervention group
Group type: COMPARATOR
Intervention: Mixture ATP (General therapy)
Number of subjects: 65
Study 3388122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 100
Study 3388122 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy
Number of subjects: 100
Study 31719073 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Programme (13 modules delivered live via videoconference over 3 months)
Number of subjects: 12
Study 31719073 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Programme
Number of subjects: 12
Study 28545400 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural medicine intervention in physiotherapy (goal-setting, self-monitoring, feedback) for 4 months
Number of subjects: 160
Study 28545400 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 25116085 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 34
Study 25116085 — intervention group
Group type: COMPARATOR
Intervention: Sham-hypoxic placebo
Number of subjects: 34
Study 23389824 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 691
Study 23389824 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300 U
Number of subjects: 691
Study 23389824 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U and 300 U
Number of subjects: 691
Study 23389824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 21615936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 73
Study 21615936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 73
Study 21615936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity and Cognitive Training (PACT)
Number of subjects: 73
Study 21615936 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control
Number of subjects: 73
Study 21615936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Training
Number of subjects: 73
Study 21615936 — intervention group
Group type: EXPERIMENTAL
Intervention: Other Participants
Number of subjects: 73
Study 18422802 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP-induced pulsatile CPB (Group B)
Number of subjects: 96
Study 18422802 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile CPB with IABP discontinued (Group A)
Number of subjects: 96
Study 22614132 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA™)
Number of subjects: 75
Study 22614132 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 75
Study 15948916 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical drug trial
Number of subjects: 0
Study 12645643 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI-1067
Number of subjects: 0
Study 9893928 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (AZ), administered over a 4-week period
Number of subjects: 0
Study 7535938 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 100 mg tid
Number of subjects: 12
Study 7535938 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 115 mg tid
Number of subjects: 12
Study 7535938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2814916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine administered orally twice a day (9 a.m. and 21 p.m.)
Number of subjects: 9
Study 791234 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg plus Ephedrine 12.5 mg
Number of subjects: 8
Study 791234 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine by mouth
Number of subjects: 8
Study 791234 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine transdermally
Number of subjects: 8
Study 791234 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 12.5 mg plus Ephedrine 25 mg
Number of subjects: 8
Study 791234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29266524 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive rehabilitation therapy program (eReCog)
Number of subjects: 76
Study 29266524 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 76
Study 28478583 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cm from the pylorus
Number of subjects: 60
Study 28478583 — intervention group
Group type: COMPARATOR
Intervention: 8 cm from the pylorus
Number of subjects: 60
Study 28478583 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cm from the pylorus (diabetic patients)
Number of subjects: 60
Study 28478583 — intervention group
Group type: COMPARATOR
Intervention: 8 cm from the pylorus (diabetic patients)
Number of subjects: 60
Study 28478583 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cm from the pylorus (non-diabetic patients)
Number of subjects: 60
Study 28478583 — intervention group
Group type: COMPARATOR
Intervention: 8 cm from the pylorus (non-diabetic patients)
Number of subjects: 60
Study 28478583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25395149 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally Laparoscopic Distal Gastrectomy (TLDG)
Number of subjects: 110
Study 25395149 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-Assisted Distal Gastrectomy (LADG)
Number of subjects: 110
Study 23339314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 83
Study 23339314 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 83
Study 21796707 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg/day
Number of subjects: 3
Study 21796707 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 6 g/day
Number of subjects: 3
Study 21796707 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 200 IU/day
Number of subjects: 3
Study 18295497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiprolisant
Number of subjects: 22
Study 18295497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16431893 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (Angiotensin II-receptor blockers)
Number of subjects: 56
Study 16431893 — intervention group
Group type: COMPARATOR
Intervention: CCB (Calcium-channel blocker)
Number of subjects: 56
Study 12908681 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 34
Study 12908681 — intervention group
Group type: COMPARATOR
Intervention: 5% sevoflurane
Number of subjects: 34
Study 12908681 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.0 mg x kg(‐1) i.v.)
Number of subjects: 34
Study 10884325 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA(A) receptor subtypes immunohistochemically analyzed with subunit‐specific antibodies (alpha1, alpha2, alpha3, beta2,3, and gamma2)
Number of subjects: 16
Study 10884325 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 16
Study 10884325 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA(A) receptor subunit staining
Number of subjects: 16
Study 10884325 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA(A) receptor alpha2‐subunit
Number of subjects: 16
Study 10884325 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA(A) receptor alpha1‐subunit
Number of subjects: 16
Study 10884325 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA(A) receptor beta2,3- and gamma2-subunits
Number of subjects: 16
Study 9389113 — intervention group
Group type: EXPERIMENTAL
Intervention: Kexue Ning (stopping hemoptysis)
Number of subjects: 0
Study 9389113 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control)
Number of subjects: 0
Study 1638070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every third day (1/2)
Number of subjects: 0
Study 1638070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every fifth day (1/4)
Number of subjects: 0
Study 1638070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every seventh day (1/6)
Number of subjects: 0
Study 1638070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate applied every ninth day (1/8)
Number of subjects: 0
Study 1638070 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6374098 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 36
Study 6374098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30157787 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery ligation
Number of subjects: 104
Study 30157787 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 27210276 — intervention group
Group type: COMPARATOR
Intervention: Medical Therapy (MT)
Number of subjects: 45
Study 27210276 — intervention group
Group type: COMPARATOR
Intervention: Amniotic Membrane Transplantation (AMT) with Medical Therapy (MT)
Number of subjects: 45
Study 27210276 — intervention group
Group type: COMPARATOR
Intervention: Topical Umbilical Cord Serum (UCS) with Medical Therapy (MT)
Number of subjects: 45
Study 26250838 — intervention group
Group type: EXPERIMENTAL
Intervention: 5Cs consultation model training (asynchronous and live)
Number of subjects: 0
Study 26250838 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 0
Study 24016491 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing (using clinical information plus genotype)
Number of subjects: 1022
Study 24016491 — intervention group
Group type: COMPARATOR
Intervention: Clinical-guided dosing (using only clinical information)
Number of subjects: 1022
Study 21397626 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline treatment for 8 weeks
Number of subjects: 0
Study 21397626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 18313446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow-dose transdermal estradiol (0.014 mg/day)
Number of subjects: 417
Study 18313446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 16983107 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy (paclitaxel 60 mg/m2 weekly)
Number of subjects: 214
Study 16983107 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (60 Gy)
Number of subjects: 214
Study 16983107 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiotherapy
Number of subjects: 214
Study 16983107 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 214
Study 16331853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based medical day-treatment program
Number of subjects: 230
Study 16331853 — intervention group
Group type: COMPARATOR
Intervention: Community-based nonmedical day treatment programs
Number of subjects: 230
Study 16331853 — intervention group
Group type: COMPARATOR
Intervention: Nonmedical site with worse outcomes
Number of subjects: 230
Study 11386894 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin in clinical practice
Number of subjects: 410
Study 11386894 — intervention group
Group type: COMPARATOR
Intervention: Warfarin in randomized trials
Number of subjects: 410
Study 9041624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFX; 8 mg/kg once daily)
Number of subjects: 313
Study 9041624 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (A/C; 40 mg/kg/day in three divided doses)
Number of subjects: 313
Study 9041624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFX)
Number of subjects: 313
Study 9041624 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (A/C)
Number of subjects: 313
Study 8181578 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 49
Study 8181578 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 3580942 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy plus MER/BCG (RCM)
Number of subjects: 44
Study 3580942 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy (RC)
Number of subjects: 44
Study 29701561 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (300 μg/day, 7 subcutaneous administrations over 1 week)
Number of subjects: 120
Study 29701561 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 120
Study 29701561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28087128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 days/40 IU twice daily)
Number of subjects: 120
Study 28087128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 120
Study 28087128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 days/10 puffs twice daily)
Number of subjects: 120
Study 26308026 — intervention group
Group type: EXPERIMENTAL
Intervention: Version B (cars in parking spaces separated from the sidewalk by grass verges and trees)
Number of subjects: 74
Study 26308026 — intervention group
Group type: COMPARATOR
Intervention: Version A (cars parked partially on the sidewalk)
Number of subjects: 74
Study 23168307 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewards-based incentive (credits on study store gift card)
Number of subjects: 58
Study 23168307 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (pre-intervention)
Number of subjects: 58
Study 20621520 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour intravenous (IV) insulin infusion (ISI) adjusted to maintain PGL within 4.5-7.0 mmol/L (81-126 mg/dL), n=26
Number of subjects: 50
Study 20621520 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin if PGL was >10.0 mmol/L (>180 mg/dL) (control group [CG]), n=24
Number of subjects: 50
Study 20621520 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour intravenous (IV) insulin infusion (ISI)
Number of subjects: 50
Study 20621520 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin if PGL was >10.0 mmol/L (>180 mg/dL) (control group [CG])
Number of subjects: 50
Study 18308081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal biopsy
Number of subjects: 246
Study 18308081 — intervention group
Group type: COMPARATOR
Intervention: Transrectal biopsy
Number of subjects: 246
Study 18308081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal and Transrectal biopsy
Number of subjects: 246
Study 16210415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid at 1.33 kcal/min for 50 min
Number of subjects: 11
Study 16210415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid at 4 kcal/min for 50 min
Number of subjects: 11
Study 16210415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid at 1.33 kcal/min for 150 min
Number of subjects: 11
Study 16210415 — intervention group
Group type: COMPARATOR
Intervention: Saline for 150 min
Number of subjects: 11
Study 12963171 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrauterine system with continuous levonorgestrel release (20 microg/24 h) combined with oral estradiol (2 mg daily)
Number of subjects: 200
Study 12963171 — intervention group
Group type: COMPARATOR
Intervention: Cyclic oral regimen of norethisterone acetate (1 mg on day 13‐22) and estradiol (days 1‐21; 2 mg, days 22‐28; 1 mg)
Number of subjects: 200
Study 10342514 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% LCT emulsion (group 1, n=6)
Number of subjects: 12
Study 10342514 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% MCT/LCT emulsion (group 2, n=6)
Number of subjects: 12
Study 8949437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate
Number of subjects: 20
Study 8949437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1807610 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 6784739 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 70
Study 6784739 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 70
Study 6784739 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotic premedication with Enflurane
Number of subjects: 70
Study 6784739 — intervention group
Group type: COMPARATOR
Intervention: Narcotic premedication with Halothane
Number of subjects: 70
Study 6784739 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane and Halothane
Number of subjects: 70
Study 29221791 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 16